Infertility Clinical Trial
— PURSUEOfficial title:
A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)
NCT number | NCT01144416 |
Other study ID # | P06029 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | June 2010 |
Est. completion date | April 2012 |
Verified date | February 2022 |
Source | Organon and Co |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to show that a single injection of SCH 900962/MK-8962 is non-inferior to daily injections of recombinant follicle-stimulating hormone (recFSH) during the first week of ovarian stimulation in terms of the number of vital pregnancies (ie, presence of at least one fetus with heart activity as assessed by ultrasound at least 35 days after embryo transfer) in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Status | Completed |
Enrollment | 1424 |
Est. completion date | April 2012 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 42 Years |
Eligibility | Inclusion Criteria: - Willing and able to provide written informed consent for trial P06029 as well as for the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the pharmacogenetic analysis (if applicable). - Female and >=35 to <=42 years of age with indication for COS and IVF/ICSI. - Body weight =50.0 kg, body mass index (BMI) >=18.0 to <=32.0 kg/m2. - Regular spontaneous menstrual cycle with variation not outside the 24-35 days. - Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). - Results of clinical laboratory tests, cervical smear, physical examination within normal limits or clinically acceptable to the investigator. - Adhere to trial schedule. Exclusion Criteria: - A recent history of/or any current endocrine abnormality. - A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS). - A history of/or current polycystic ovary syndrome. - More than 20 basal antral follicles <11 mm (both ovaries combined) in the early follicular phase. - Less than 2 ovaries or any other ovarian abnormality. - Unilateral or bilateral hydrosalpinx. - Intrauterine fibroids =5 cm or any clinically relevant pathology, which could impair embryo implantation or pregnancy continuation. - More than three unsuccessful COS cycles for IVF/ICSI since the last established ongoing pregnancy (if applicable). - A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment. - A history of recurrent miscarriage. - FSH >15.0 IU/L or luteinizing hormone (LH) >12.0 IU/L during the early follicular phase. - Positive for human immunodeficiency virus (HIV) or Hepatitis B. - Contraindications for the use of gonadotropins or gonadotropin releasing hormone (GnRH) antagonists. - A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment. - Smoking or recently stopped smoking (ie, within the last 3 months prior to signing informed consent). - A recent history or presence of alcohol or drug abuse. - The participant or the sperm donor has known gene defects, genetic abnormalities, or abnormal karyotyping, relevant for the current indication or for the health of the offspring. - Prior or concomitant medications disallowed by protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Organon and Co |
Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, Elbers J, Gordon K, Mannaerts B; Pursue investigators. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared wi — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With a Vital Pregnancy | Vital pregnancy was defined as the presence of at least 1 fetus with heart activity at least 35 days (=5 weeks) after embryo transfer in the controlled ovarian stimulation (COS) treatment cycle | Vital pregnancy will be assessed by ultrasound at least 35 days after embryo transfer (with a timeframe of 35-42 days). Time from start of study treatment to embryo transfer is maximally 24 days. | |
Secondary | Number of Oocytes Retrieved Per Attempt | The number of cumulus oocyte-complexes retrieved was summarized per treatment group and per attempt (= per started COS cycle). | Maximally 21 days after the start of study treatment. | |
Secondary | Live Birth Rate | The live-birth rate is the percentage of participants with at least 1 live born infant after an ongoing pregnancy in the controlled ovarian stimulation (COS)treatment cycle relative to the number of participants treated. | Approximately nine months after embryo transfer | |
Secondary | Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS) | Grade II (moderate OHSS) is characterized by distinct ovarian cysts (ovary size 8-10 cm), accompanied by abdominal pain and tension, nausea, vomiting, diarrhea. Grade III (severe OHSS) is characterized by enlarged cystic ovaries (ovary size >10 cm), accompanied by ascites and occasionally hydrothorax. Abdominal tension and pain may be severe. Pronounced hydrothorax together with an abdominal cavity filled with cysts and fluid elevating the diaphragm, may cause severe breathing difficulties. Large quantities of fluid inside the cysts and in the peritoneal and pleural cavities cause hemoconcentration and increased blood viscosity. In rare cases, the syndrome may further be complicated by the occurrence of thromboembolic phenomena. |
Up to approximately 1 month after oocyte pick-up | |
Secondary | Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event | The number of participants who started stimulation but did not undergo embryo transfer due to (S)AEs will be compared between the treatment groups. | Up to time of embryo transfer (maximum of 24 days after start of study drug) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |